Kratom is banned or restricted in several countries and a handful of U.S. states because regulators classify it as a public safety risk. The core concerns center on its opioid-like effects, the potential for dependence, contamination in unregulated products, and deaths reported in people who used it. But the legal picture is more complicated than a simple yes-or-no: kratom remains legal at the federal level in the United States, a proposed national ban was withdrawn after public backlash, and the World Health Organization has not recommended international control.
How Kratom Acts on the Brain
Kratom leaves contain two active compounds that interact with the same brain receptors targeted by opioids like morphine and fentanyl. The more abundant one, mitragynine, binds weakly to those receptors and behaves quite differently from classic opioids. In lab studies using human receptors, mitragynine showed no significant activation even at high concentrations, though it still produces opioid-like effects in living animals, likely because the body converts some of it into the second compound or because it acts on other brain pathways simultaneously.
That second compound, 7-hydroxymitragynine, is far more potent. It binds to opioid receptors about nine times more strongly than mitragynine and partially activates them, producing sedation, pain relief, and the euphoria that drives repeated use. For comparison, morphine and fentanyl fully activate these same receptors. The partial activation is a key distinction: it means kratom’s ceiling effect is lower, which some researchers argue could make it less dangerous in overdose but still capable of causing dependence.
This pharmacology is what puts kratom in regulatory crosshairs. It doesn’t fit neatly into existing drug categories. At low doses, users report stimulant-like energy. At higher doses, the opioid effects dominate. That dual nature makes it difficult for agencies to evaluate using frameworks built for single-mechanism drugs.
The DEA’s Failed Scheduling Attempt
In August 2016, the Drug Enforcement Administration announced its intention to place kratom’s two active compounds on Schedule I of the Controlled Substances Act, the most restrictive category reserved for substances with “a high potential for abuse, no currently accepted medical use, and a lack of accepted safety for use under medical supervision.” The agency framed the move as necessary to “avoid an imminent hazard to public safety.”
The proposal triggered an unusually fierce public response. Tens of thousands of comments flooded in from kratom users, many of whom said they relied on it to manage chronic pain or to stay off prescription opioids. Members of Congress from both parties pushed back. Within weeks, the DEA took the rare step of withdrawing its notice of intent, instead requesting a scientific review from the FDA. That review has never resulted in a scheduling action, and kratom remains unscheduled at the federal level as of 2025.
The FDA’s Safety Case Against Kratom
While the DEA stepped back, the FDA has maintained a firm stance. The agency has warned consumers not to use kratom, citing risks of liver toxicity, seizures, and substance use disorder. It points to kratom’s ability to produce “classic opioid-related effects” including sedation, nausea, constipation, physical dependence, and respiratory depression that can be fatal.
The FDA has also raised concerns about what’s actually in kratom products sold to consumers. In testing of 30 different kratom products from various sources, the agency found significant levels of lead and nickel exceeding safe daily exposure limits for oral intake. Some products were dramatically contaminated. One product contained nickel at 20,100 nanograms per gram, and several others had lead levels in the 400 to 600 nanogram-per-gram range. For heavy users consuming kratom multiple times daily, cumulative exposure could potentially cause nervous system damage, kidney problems, anemia, high blood pressure, or increased cancer risk. A separate salmonella outbreak was also traced to kratom products, reinforcing the FDA’s argument that the lack of manufacturing standards creates real danger.
Deaths Linked to Kratom
The strongest card regulators play is mortality data. A CDC report covering July 2016 through December 2017 identified 152 overdose deaths where kratom was detected in postmortem toxicology. Medical examiners ruled kratom a contributing cause of death in 91 of those cases. However, only seven of those 152 decedents tested positive for kratom alone, with no other substances detected, and even in those cases the CDC noted that the presence of additional substances “cannot be ruled out.”
This is where the debate gets contentious. Kratom advocates argue that the vast majority of these deaths involved other drugs, often fentanyl, heroin, or benzodiazepines, making it impossible to attribute them to kratom itself. Regulators counter that kratom’s opioid activity can compound the respiratory depression caused by other substances, making polydrug combinations more lethal than they would otherwise be.
Dependence and Withdrawal
Regular kratom use can lead to physical dependence. Surveys and clinical case reports show that people who use high amounts (roughly more than 3 grams of leaf material multiple times daily) for extended periods may experience withdrawal symptoms within a day of stopping. Those symptoms overlap with opioid withdrawal: runny nose, muscle pain, diarrhea, lethargy, depressed mood, and anxiety.
The severity, though, appears to be a different story. A scientific expert forum reviewing the available evidence concluded that kratom withdrawal is “generally milder than observed with chronic frequent opioid, sedative, or stimulant users and generally more tolerable and self-manageable.” Cravings vary widely from person to person. Management typically involves gradual dose reduction or non-opioid medications that ease withdrawal discomfort. This milder withdrawal profile is part of why some users and researchers see kratom as a potential bridge away from more dangerous opioids, even as regulators see any dependence potential as a reason for restriction.
Where Kratom Is Actually Banned
Kratom is not under international control. The World Health Organization’s Expert Committee on Drug Dependence has reviewed it but has not recommended scheduling under UN treaties. Several Southeast Asian countries where kratom grows natively, including Thailand, historically banned it, though Thailand reversed its ban in 2021 and now permits regulated sale.
In the United States, the legal landscape is a patchwork. Six states have banned kratom outright: Alabama, Arkansas, Indiana, Rhode Island, Vermont, and Wisconsin. Several others have passed versions of the Kratom Consumer Protection Act, which takes the opposite approach. Instead of banning kratom, these laws regulate it: requiring age verification, product labeling, and limits on contaminants. Utah was among the first states to adopt this framework, and others have followed. The logic is that since people will use kratom regardless, setting manufacturing and labeling standards is safer than prohibition.
Why the Debate Remains Unresolved
Kratom occupies an uncomfortable middle ground. Its active compounds clearly interact with opioid receptors, but they do so in ways that are pharmacologically distinct from heroin, fentanyl, or prescription painkillers. The contamination problem is real but is arguably a consequence of the lack of regulation rather than an inherent property of the plant. The death toll is concerning but hard to disentangle from polydrug use. And the very population most likely to use kratom, people managing chronic pain or trying to quit stronger opioids, is the population most vulnerable to being harmed by either unrestricted access or a total ban.
Regulators who favor bans point to the precautionary principle: the safety profile is not well enough established to let millions of people self-medicate with an opioid-active substance sold without quality controls. Opponents argue that banning kratom would push users back toward more dangerous opioids at a time when overdose deaths from fentanyl continue to climb. Both sides have data supporting their position, which is precisely why kratom’s legal status remains fractured and politically charged.